Whilst anti-IL-17A antibodies have been licensed for clinical use against psoriasis, their effect in treating IL-17A dependent airway inflammation has been equivocal5 and might be fraught with significant side effects due to the loss of efficient pathogen control in the airways. Here, IL17A is linked to psoriasis.